Using tools requires that the brain is able to control movements
Milan, Italy, 20 April 2009 - Our ability to use objects and tools to perform actions is essential to our daily activities, and it is developed to a level that is unique to our species. In a study performed by a scientific team of the French National Center for Scientific Research (CNRS) and the Paris Descartes University, published by Elsevier in the April 2009 issue of Cortex, researchers have found that brain-lesioned patients who have difficulties using familiar objects and tools in their usual context (e.g. cutting paper with scissors) may also be impaired at controlling the movement of an object in the context of simpler movements such as pointing at a target.
Patients suffering from apraxia, a neurological syndrome caused by lesions in the left hemisphere of the brain, have difficulties executing complex movements, including tool use gestures. In this study, the authors compared the performance of apraxics to that of other patients suffering from left cerebral lesion but showing no sign of apraxia, on a task requiring them to point at targets with a stick. Apraxics performed significantly worse than control patients, committing larger errors and sometimes failing to anticipate the changes in movement coordination imposed by the use of a long object to point at a target within hand reach.
Apraxia is often thought to be due to a loss in the ability to translate memories of well-learned gestures into a specific sequence of movements. With these new findings, the authors suggest that some of those patients are also impaired in more elementary processes that allow the incorporation of an object as a functional extension of their limb into their body coordination.
# # #
Notes to Editors:
The article is “The use of a tool requires its incorporation into the movement: Evidence from stick-pointing in apraxia” by Stéphane Jacobs, Bernard Bussel, Michele Combèaud and Agnès Roby-Brami appears in Cortex, Volume 45, Issue 4 (April 2009), published by Elsevier in Italy.
Full text of the article featured above is available to members of the media upon request. Please contact the Elsevier press office,firstname.lastname@example.org. To schedule an interview, contact Dr. Stéphane Jacobs, email@example.com.
Cortex is an international journal devoted to the study of cognition and of the relationship between the nervous system and mental processes, particularly as these are reflected in the behaviour of patients with acquired brain lesions, normal volunteers, children with typical and atypical development, and in the activation of brain regions and systems as recorded by functional neuroimaging techniques. It was founded in 1964 by Ennio De Renzi. The Editor in-chief of Cortex is Sergio Della Sala, Professor of Human Cognitive Neuroscience at the University of Edinburgh. Fax: 0131 6513230, e-mail: firstname.lastname@example.org. Cortex is available online at http://www.sciencedirect.com/science/journal/00109452
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
+39 2881 84260